Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience.
10.4174/astr.2014.87.2.61
- Author:
Kagan KARABULUT
1
;
G Selcuk OZBALCI
;
Tugrul KESICIOGLU
;
Ismail Alper TARIM
;
Gokhan LAP
;
Ayfer KAMALI POLAT
;
Ilhan KARABICAK
;
Kenan ERZURUMLU
Author Information
1. Department of General Surgery, Ondokuz Mayis University Medical School, Samsun, Turkey. kagankarabulut@hotmail.com
- Publication Type:Original Article
- Keywords:
Albendazole;
Hepatic echinococcosis;
Recurrence
- MeSH:
Albendazole*;
Echinococcosis;
Echinococcosis, Hepatic*;
Follow-Up Studies;
Humans;
Recurrence
- From:Annals of Surgical Treatment and Research
2014;87(2):61-65
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis. METHODS: One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 +/- 14.34 days before the surgery, and it was continued for 4.39 +/- 3.11 months postoperatively. A total of 1.7 microg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 +/- 51.56 months. RESULTS: Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively. CONCLUSION: Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.
